LY266097, >=98% (HPLC), powder

Descriptions

Biochem/physiol Actions

LY266097 is a selective 5HT-2B antagonist with a pKI of 9.7 for the human cloned 5-HT2B receptor and a 100-fold greater selectivity for 5-HT2B than the human 5-HT2C and 5-HT2A.

Features and Benefits

This compound was developed by Eli Lilly. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Packaging

5, 25 mg in glass bottle

Specifications

Colour	white to tan
Quality Level	100
InChI key	KPXKZZURYAXZQE-UHFFFAOYSA-N
InChI	1S/C21H23ClN2O2.ClH/c1-12-4-6-16-15(10-12)14-8-9-23-17(20(14)24-16)11-13-5-7-18(25-2)21(26-3)19(13)22;/h4-7,10,17,23-24H,8-9,11H2,1-3H3;1H
Manufacturer	SIGMA-ALDRICH
Form	powder
Assay	≥98% (HPLC)